Clovis Oncology (CLVS) Soars: Stock Adds 13.2% is Session – Tale of the Tape

ZacksClovis Oncology, Inc. (CLVS) was a big mover last session, as its shares rose over 13% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the trend for the company since Sep 3, as the stock is now trading above the volatile price range of $40.02 to $46.08.

In the last 30 days, the company did not witness any estimate revision and the Zacks Consensus Estimate also remained unchanged. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Clovis Oncology currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

Some better-ranked stocks worth considering in the med-biomed gene industry include Cambrex Corporation. (CBM), Gilead Sciences Inc. (GILD) and InSite Vision Incorporated (INSV). All these stocks sport a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.

Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.

Be the first to comment

Leave a Reply